Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

13.64 +0.04 (+0.29%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9

...

32 33 Next >

RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care. ↗

February 12, 2025

The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks.

Via Investor's Business Daily

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 05, 2025

From Compass Pathways plc

Via Business Wire

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

January 21, 2025

From Compass Pathways plc

Via Business Wire

Uncovering Potential: Compass Pathways's Earnings Preview ↗

October 30, 2024

Via Benzinga

Compass Pathways Announces Pricing of Underwritten Offering

January 10, 2025

From Compass Pathways plc

Via Business Wire

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

December 18, 2024

From Compass Pathways plc

Via Business Wire

Is Your Mind Ready to Consider Investing in Psychedelics Stocks? ↗

November 29, 2024

Don't jump in without doing some research first.

Via The Motley Fool

Compass Pathways to Participate in December Investor Conferences

November 25, 2024

From Compass Pathways plc

Via Business Wire

COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co? ↗

November 25, 2024

COMPASS Pathways faces $43M market cap loss, raising concerns among institutional investors holding 30% ownership.

Via Benzinga

Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday ↗

November 15, 2024

Via Benzinga

Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS ↗

November 15, 2024

President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services.

Via Investor's Business Daily

Topics Government

FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment ↗

November 14, 2024

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory hurdles.

Via Benzinga

AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care? ↗

November 13, 2024

AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care.

Via Benzinga

Topics Artificial Intelligence

Top 3 Health Care Stocks You'll Regret Missing In November ↗

November 05, 2024

Via Benzinga

Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript ↗

October 31, 2024

CMPS earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Nasdaq Down 500 Points; Uber Shares Dip After Q3 Results ↗

October 31, 2024

Via Benzinga

As Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash ↗

October 31, 2024

Compass Pathways delays key Phase 3 psilocybin trial readouts, triggering a 30% workforce reduction amid efforts to conserve cash and refocus.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 31, 2024

Via Benzinga

Crude Oil Gains 1%; Meta Shares Fall Following Q3 Results ↗

October 31, 2024

Via Benzinga

Estée Lauder, Robinhood, eBay And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

October 31, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 31, 2024

Via Benzinga

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

October 31, 2024

From Compass Pathways plc

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 25, 2024

Via Benzinga

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

October 24, 2024

From Compass Pathways plc

Via Business Wire

Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes ↗

October 07, 2024

Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential.

Via Benzinga

Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder ↗

September 26, 2024

New study suggests psilocybin may help treat body dysmorphic disorder by rewiring brain connectivity and reducing obsessive thought patterns.

Via Benzinga

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

September 23, 2024

From Compass Pathfinder Limited

Via Business Wire

Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week ↗

September 15, 2024

The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come.

Via Talk Markets

MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward? ↗

September 12, 2024

Via Benzinga

Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th ↗

September 10, 2024

While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

32 33 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.